| 1.2 0.08 (7.14%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.83 | 1-year : | 2.14 |
| Resists | First : | 1.56 | Second : | 1.83 |
| Pivot price | 1.16  |
|||
| Supports | First : | 0.97 | Second : | 0.6 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.09 |
| MA(100) : | 1.44 |
MA(250) : | 3.09 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50 |
D(3) : | 58.7 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 6.8 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RVPH ] has closed below upper band by 44.5%. Bollinger Bands are 26.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.21 - 1.22 | 1.22 - 1.23 |
| Low: | 1.05 - 1.06 | 1.06 - 1.07 |
| Close: | 1.18 - 1.2 | 1.2 - 1.21 |
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Mon, 09 Sep 2024
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - StockTitan
Wed, 04 Sep 2024
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Wed, 04 Sep 2024
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Wed, 21 Aug 2024
Reviva Pharmaceuticals Announces Pricing of $5.0 Million - GlobeNewswire
Wed, 21 Aug 2024
Reviva Pharmaceuticals Launches Multi-Million Share Offering - TipRanks
Fri, 16 Aug 2024
Maxim Group Downgrades Reviva Pharmaceuticals Holdings (RVPH) - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 14.9 (%) |
| Held by Institutions | 21.6 (%) |
| Shares Short | 5,460 (K) |
| Shares Short P.Month | 4,450 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -234 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.91 |
| PEG Ratio | 0 |
| Price to Book value | -6 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|